Tianfeng Xu
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
41
Citations
1,873
Est. group size
~16
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~11 · 0% small-team papers (≤3 authors) · across 11 venues
- Design, Synthesis, and Structure–Activity Relationship Studies of 7 <i>H</i> -Pyrrolo[2,3- <i>d</i> ]pyrimidine Derivatives as Potent Casein Kinase 1α (CK1α) Inhibitors
ACS Medicinal Chemistry Letters · 2026
- An overview of PROTACs targeting KRAS and SOS1 as antitumor agents
Bioorganic & Medicinal Chemistry Letters · 2025
- M2c Macrophages Mediate <scp>YAP1</scp> to Promote Vascularized Bone Regeneration in Distraction Osteogenesis
The FASEB Journal · 2025
- Targeting Cbl-b by a small molecular inhibitor potentiates T cell receptor signaling and suggests rational combination strategies
International Immunopharmacology · 2025
- Design, Synthesis, and Biological Evaluation of Potent and Selective PROTAC Degraders of Oncogenic KRAS<sup>G12D</sup>
Journal of Medicinal Chemistry · 2024
- Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders
ACS Medicinal Chemistry Letters · 2024
- Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor
Bioorganic & Medicinal Chemistry Letters · 2024
- Design, Synthesis, and Biological Evaluation of 2,4-Diaminopyrimidine Derivatives as Potent CDK7 Inhibitors
ACS Medicinal Chemistry Letters · 2024
- An updated patent review of SOS1 inhibitors (2022–present)
Expert Opinion on Therapeutic Patents · 2024
- Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Science Bulletin · 2023
- Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
Journal of Medicinal Chemistry · 2023
- Design, Synthesis, and Bioevaluation of Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Potent SOS1 Inhibitors
ACS Medicinal Chemistry Letters · 2023
- Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy
Nature Communications · 2022
- Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations
Journal of Medicinal Chemistry · 2022
- Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation
ACS Medicinal Chemistry Letters · 2022
- Journal of Medicinal Chemistry×12
- ACS Medicinal Chemistry Letters×5
- Bioorganic & Medicinal Chemistry Letters×3
- Cancer Research×2
- The Cambridge Structural Database×2
- Bo Wen
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Hoda Metwally
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Haibin Zhou
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Xin Han
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Mi Wang
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile